OneStream, Inc. Class A Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Shea
- Full Time Employees
- 1,500
- Sector
- Technology
- Industry
- Software - Application
- Address
- 191 N Chester Street Birmingham DE United States of America
- IPO Date
- Jul 11, 2005
- CIK
- 0001889956
- Website
- onestream.com
- Similar Companies
- Business
- OneStream, Inc. (NASDAQ:OS) provides a unified AI-enabled enterprise finance platform that modernizes core financial functions for complex organizations worldwide; its Digital Finance Cloud offers financial close and consolidation to automate reporting and compliance tasks; financial and operational planning, budgeting, forecasting, and analysis for synchronized enterprise-wide results; reporting, analytics, and business intelligence with end-to-end visibility for executives, finance teams, and business units; account reconciliations; people, capital, and thing planning; tax provisioning; data quality management; and extensible AI-powered applications including Sensible ML and SensibleAI Agents. Founded in 2012 and headquartered in Birmingham, Michigan, the company serves over 1,600 enterprises, mid-market organizations, and government entities across more than 45 countries in North America, South America, EMEA, and APAC through a network of over 300 global partners such as Accenture, IBM, KPMG, and PwC. OneStream completed its initial public offering on July 24, 2024, at $20 per share; raised $465 million in a post-IPO secondary sale in November 2024 led by D1 Capital Partners and Tiger Global Management; acquired the remaining equity of DataSense in May 2024 for approximately $30 million to advance AI solutions; deepened its strategic partnership with Microsoft to embed SensibleAI Agents into Microsoft 365, earning Microsoft's 2025 SDC Partner of the Year for the Americas; and launched the OneStream Solution Exchange marketplace alongside AI innovations driving quadrupling Finance AI bookings.
Company News
OneStream (NASDAQ:OS) and Dassault Systemes (OTCMKTS:DASTY) Head to Head Analysis
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
AstraZeneca Reports Positive Lung Cancer Trials Amid Pipeline Setback
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Gabelli Funds LLC Makes New Investment in OneStream, Inc. $OS
Annis Gardner Whiting Capital Advisors LLC Grows Position in OneStream, Inc. $OS
Advanced Polymer Coatings (APC) Collaborates with Albert Invent to Scale the Future of Modern R&D Infrastructure for Coatings
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer